Viral pathogens causing global disease burdens are often characterised by high rates of evolutionary changes, facilitating escape from therapeutic or immune selective pressure. Extensive viral diversity at baseline can shorten the time to resistance emergence and alter mutational pathways, but the impact of genotypic background on the genetic barrier can be difficult to capture, in particular for antivirals in experimental stages, recently approved or expanded into new settings. We developed an evolutionary-based counting method to quantify the population genetic potential to resistance and assess differences between populations. We demonstrate its applicability to HIV-1 integrase inhibitors, as their increasing use globally contrasts with limited availability of non-B subtype resistant sequences and corresponding knowledge gap on drug resistance. A large sequence dataset encompassing most prevailing subtypes and resistance mutations of first-and second-generation inhibitors were investigated. A varying genetic potential for resistance across HIV-1 subtypes was detected for 15 mutations at 12 positions, with notably 140S in subtype B, while 140C was discarded to vary across subtypes. An additional analysis for HIV-1 reverse transcriptase inhibitors identified a higher potential for 65R in subtype C, on the basis of a differential codon usage not reported before. The evolutionary interpretation of genomic differences for antiviral treatment remains challenging. Our framework advances existing counting methods with an increased sensitivity that identified novel subtype dependencies as well as rejected previous statements. Future applications include novel HIV-1 drug classes as well as other viral pathogens. 1 Introduction 1 The advent of antiviral treatment resulted globally in significant health gains and 2 averted deaths by preventing viral infections and improving disease outcomes. Major 3 human pathogens targeted by antivirals are fast-evolving, genetically diverse 4 viruses [13, 19, 20] , allowing for rapid adaptation through the emergence of 5 1/16 resistance-conferring mutations. A key concept in understanding the dynamics of 6 resistance development is the genetic barrier, which ultimately quantifies the 7 evolutionary time to viral escape from drug selective pressure [4, 14, 16, 39] . The virus 8 make-up at baseline can shorten the evolutionary distance to antiviral resistance and, 9 together with treatment-and patient-related factors, alter the mode and tempo of 10 resistance emergence [20, 24] . The imprint of genotypic background on viral escape 11 dynamics can be however difficult to capture. In particular for newer antivirals when 12 resistance knowledge is initially limited to in vitro selection experiments informed on 13 genetically-limited backbones and inferred from observations in well-controlled clinical 14 studies or patient cohorts underrepresenting the full spectrum of viral diversity. 15 A notable example of success is the evolution of the management of Human 16 Immunodeficiency Virus type-1 (HIV-1) infection in the last three decades, with 17 antivirals available from multiple drug classes that drastically reduced morbidity and 18 mortality related to HIV-1. The recent class of integrase strand transfer inhibitors 19 (INSTIs), directed against the integrase enzyme by blocking the strand transfer step of 20 viral DNA integration, has considerably expanded treatment options and reduced the 21 probability of virological failure, predominantly in resource-rich settings where INSTI 22 use is widespread. To date, first-generation INSTIs raltegravir (RTG) and elvitegravir 23 (EVG) and second-generation INSTIs dolutegravir (DTG) and bictegravir (BIC) are 24
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ignored subtype-specific effects or analyzed limited subtype distributions and relied on 49 arbitrary substitution cost assignments. retained, and triplets with a prevalence above 50% were defined as predominant for that 93 sub-epidemic. The prevalence of resistance mutations and codon entropy were inferred 94 from the triplet distribution. 95 
Substitution cost 96
A penalty score is assigned to the different types of nucleotide substitution through the 97 transformation of empirically estimated substitution matrices into corresponding cost 
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This transformation assigns the substitution with the highest rate (e.g. G→A) a cost 101 of 1, and the costs of the other substitutions were proportionally adapted to this enumerate all triplets that translate into R and will refer to this set as {R t,j }. First, we 114 determine a score for a given wild type triplet W T t to R, while considering all triplets 115 that translate into R (i.e., {R t,j }):
where Cost (.) quantifies the cumulative substitution cost to mutate from a W T t into a 117 particular resistance triplet R t,a , as provided in Equation 3 . This summation 118 incorporates all possible evolution paths and subsequently assigns lower cumulative 119 costs (i.e., more likely mutation pathways) a higher contribution to the total triplet 120 score. Taking into account different but almost equally likely evolution paths, compared 121 to only considering the minimum cumulative substitution cost, results in an elevated 122 sensitivity to detect subtype-dependencies in the genetic barrier. 123 To compute the cumulative substitution cost for R t,a (i.e., subst (W T t , R t,a )), we 124 compute the sum of the substitution cost for each triplet position, using substitution 125 matrices M c ci as defined in section 2.3:
Finally, the genetic barrier GB E is defined as the sum of the scores (Equation 2) of 127 the different wild type triplets in sub-epidemic E, weighted according to their prevalence: 128
A GB E (R) is obtained for each resistance-associated mutation and subtype. In order 129 to visualise most pronounced differences between sub-epidemics, we calculated the Figure 1 . Overview of methodology for integrase resistance amino acid S (Raa) at position 140 (Pos).
[A] Determine the distribution wild-type triplets (WTt) naturally present, the translated amino acid (WTaa) and their frequency across the 8 subtypes.
[B] A score is assigned to each wild-type triplet to evolve into the resistance mutation S.
[C] This score is obtained by iteratively determining the cumulative substitution cost for the change of WTt into each resistance triplet (Rt) translating into the amino acid S, and subsequently by the summation of the different cumulative costs.
[D] Each score is iteratively weighted by the subtype frequency of the wild-type triplet, here shown for subtype A.
[E] A population estimate of the genetic barrier is obtained for subtype A. This procedure is done for each subtype, resulting in a subtype-specific population genetic barrier for 140S. When all resistance-associated mutations are considered, a matrix of genetic barrier values is created where subtypes are shown as rows and mutations as columns. Figure 4 illustrates the visualisation of this matrix. this within-subtype variation is translated into the presence of polymorphic mutations. 161 Figure 3 shows the prevalence of resistance-associated mutations in the dataset (10.6%), 74M (10.2%), 157Q (8.3%) and 97A (5.5%); for subtype D 203M (15.3%), 97A 167 (6.2%) and 165I (6.2%); for subtype F 165I (30.2%), 50I (9.2%), 163R (6.2%) and 163K 168 (5.4%); for subtype G 50I (15.1%), 74I (10.3%) and 165I (5.3%). These results illustrate 169 both resistance-associated mutations prevalent across subtypes (e.g. 50I and 74I) as well 170 as subtype-specific occurrences (e.g. 156N). 
Calculated genetic barrier 187
The observed baseline differences in triplet frequency between subtypes will only impact 188 the genetic barrier to resistance when they are also accompanied by variation in triplet 189 6/16
scores. Subtype frequencies of wild-type nucleotide triplets, translated amino acids and 190 associated cumulative substitution costs are available as Supplementary Material. 
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Finally, combining into a complex interplay, reported results on genetic diversity and 210 evolutionary costs can be captured into a single value denoting a population-based 211 genetic potential for an INSTI mutation and subtype (Figure 4 and Figure 4 ).
212
Significant differences in calculated genetic barrier were observed for 15 mutations at 12 213 positions (Figure 4) , with a lower resistance potential for 50I (subtype D), 54I 
233
Supplementary Material provides more comparative analyses on the impact of using 234 empirically versus arbitrary defined substitution matrices. Figure 4 . The upper panel shows the estimated population genetic barrier for each combination of a resistance-associated mutation and a subtype. A higher value (red) represents an increased potential for adaptation and is indicative for a lower genetic barrier to resistance. A subtype-specific value of this population genetic barrier is calculated by first assigning each wild-type triplet with a score that indicates the ease to evolve into the resistance amino acid (See the Methods section for a detailed description how this cost score for a wild-type triplet is derived). Next, the sum of all triplet scores is weighted by the triplet prevalence so that most frequent triplets have a larger impact on the population genetic barrier estimate. The lower panel shows for each subtype the average difference in population genetic barrier from the other subtypes. A lower genetic barrier to resistance for that subtype compared to the other subtypes is shown in red while a higher genetic barrier is shown in green.
4 Discussion: 236 We developed an intuitive and novel methodology to quantify the evolutionary potential 237 for viral escape from selective pressure in fast-evolving viruses, and presented an non-optimal [2, 11, 29] . Viral adaptation to INSTI pressure through mutational 244 pathways has been well reported, but the role of natural nucleotide variation on 245 resistance development is less well understood [10, 17] . Additionally to resistance 246 mutations present at baseline, differential codon usage can affect the mode and tempo 247 of INSTI resistance pathways [23, 38] . This study presented here provided new insights 248 into the processes underlying INSTI resistance development by quantifying the genetic 249 barrier to resistance.
250
A large dataset of globally prevailing HIV-1 subtypes was investigated for their 251 evolutionary potential for viral escape from all INSTIs available for HIV-1 treatment.
252
This study confirms the non-polymorphic amino acid nature of most INSTI resistance 253 positions [25, 35] , as primarily single subtype-specific occurrences of 254 resistance-associated mutations at low frequencies were detected. By contrast, variable 255 codon predominance across subtypes was more pronounced and consequently we B   50I  51Y  54I  66A  66I  66K  68I  74I  74M  75I  92A  92G  95K  97A  114Y  119R  121Y  125K  128T  138A  138K  140S  142T  143C  143H  143S  145S  146K  146P  146R  147G  148H  148K  148R  151A  151I  153F  153Y  154I  155H  155S  155T  156N  160N  163K  163R  165I  166S  170A  203M  230G  230N  230R  232N Mutation Population Genetic Barrier Figure 5 . Each of 8 panels shows the estimated population genetic barrier for a single subtype, with the estimate either calculated as described in the Methods section (blue) or calculated by a simpler but similar methodology (red). Instead of obtaining the cost score for each wild-type triplet by summing all possible cumulative costs (blue), thereby taking into account almost equally likely substitution pathways of a wild-type triplet to the resistance amino acid, a cost score can also be calculated by only using the minimum cumulative cost (red) and therefore only considering the shortest substitution pathway to the resistance amino acid and ignoring other but almost equally likely mutational pathways to resistance. To increase the comparability of the two measures, we also took the negative exponential of the minimum score. Only increases in values are possible due to the summation, and we restricted the figure to the subset of mutations with a difference larger than 0.01.
compensating for defects in replication capacity [37] , were characterised by increased 262 variability in diversity and associated scores. Most notably was the varying potential for 263 9/16
140S in subtype B viruses, confirming previous findings [23, 32] , which is an accessory 264 mutation often occurring in combination with 148H. We and others have indeed 265 previously reported the preference of the 148H pathway in treatment-experienced 266 patients infected with subtype B viruses [17, 38] .
267
Our framework improves related counting studies at several stages. Previous studies 268 calculated the genetic barrier by only distinguishing between transitions and 269 transversions, following an approach developed for the HIV-1 protease and reverse 270 transcriptase enzymes [43] . We applied an empirically-derived and evolutionary-based 271 cost for each possible substitution and triplet position, which resulted in an increased 272 detection sensitivity, in particular transversions displayed substantial variation in costs 273 compared to the arbitrary defined values in other studies. Furthermore, we take into 274 account cost scores from all possible pathways, compared to restricting to the minimum 275 score. This approach allowed to detect relevant increases in the estimated evolutionary 276 potential (e.g. 74I), in particular for positions with high level of codon variability. To Stanford HIV drug resistance database [35] , which strengthens our finding. A complete 282 in-depth comparison of our findings with these studies is hindered by their limited 283 number of HIV-1 subtypes and INSTI resistance mutations included. As most genetic 284 barrier information to date has been established for the historical drug class of RTIs, we 285 also applied our approach to the RT enzyme. Subtype-dependencies in genetic barrier 286 both previously predicted and observed in clinical practice could be confirmed (e.g.
287
106M in subtype C). However, compared to related RTI counting studies [43] , the 288 increased sensitivity of our method also resulted in the identification of a higher 289 potential for 65R in subtype C. A higher selection rate of 65R in this subtype has been 290 well established [40] and attributed to a mechanistic basis of template factors [7] . 291 However, an explanation by codon usage has been discarded [7] , although we suggest an 292 additional impact of codon usage when all possible paths are taken into account.
293
While our framework provides a population-based cost for a single position, it only 294 represents a simplified estimate of the actual in vivo genetic barrier, which results from 295 a multi-modal interplay that eventually defines the evolutionary time to drug resistance. 296 Selection of a mutation and its rate of fixation heavily depend on factors such as patient 297 adherence, treatment potency, impact on viral fitness and (non-additive) epistatic 298 mutational interactions. Positions implicated in immune escape (e.g. 125) can also 299 further influence the rate of resistance accumulation [8, 41] . It can be difficult to obtain 300 information on all these influencing factors in a timely manner and hence to construct 301 an accurate model capturing resistance evolutionary dynamics. When such an adequate 302 model is lacking, our distance-based method offers a valuable alternative to assess the 303 genetic barrier to resistance. Our methodology however can not predict novel 304 resistance-associated mutations or subtype-specific pathways. A cost matrix was used 305 for all subtypes assuming that substitution rates are equal between subtypes, however, 306 the use of group-specific cost matrices can be accommodated by our framework. B   50I  51Y  54I  66A  66I  66K  68I  74I  74M  75I  92A  92G  95K  97A 203M  230G  230N  230R  232N 
